IMPLANET announced the successful completion of the first surgical procedures using the JAZZ system in China. As part of a distribution partnership signed in November 2022, IMPLANET and Sanyou Medical have completed the regulatory registration of the JAZZ range on the Chinese market.
In July 2025, the JAZZ system obtained regulatory approval from the CFDA in China, paving the way for its commercialization there. The first shipment of implants, invoiced to Sanyou Medical, took place in September 2025.
Ludovic Lastennet, CEO of IMPLANET, said: “The completion of the first procedures using the JAZZ system in China marks a major strategic milestone for IMPLANET. It is the result of several years of close collaboration with our partner Sanyou Medical, from regulatory registration to clinical deployment. The CFDA approval and the successful first surgeries are a testament to the clinical value of the JAZZ system in a key market, the largest in the world by volume potential. We are especially proud of the training and knowledge transfer achieved with the support of leading French spine surgeons, ensuring the system is used in line with the highest international standards of quality and safety. The upcoming surgeries scheduled in Shanghai and Beijing reflect our ambition to support a structured, progressive, and sustainable rollout of the JAZZ system across China’s major reference hospitals.”
IMPLANET announced the successful completion of the first surgical procedures using the JAZZ system in China. As part of a distribution partnership signed in November 2022, IMPLANET and Sanyou Medical have completed the regulatory registration of the JAZZ range on the Chinese market.
IMPLANET announced the successful completion of the first surgical procedures using the JAZZ system in China. As part of a distribution partnership signed in November 2022, IMPLANET and Sanyou Medical have completed the regulatory registration of the JAZZ range on the Chinese market.
In July 2025, the JAZZ system obtained regulatory approval from the CFDA in China, paving the way for its commercialization there. The first shipment of implants, invoiced to Sanyou Medical, took place in September 2025.
Ludovic Lastennet, CEO of IMPLANET, said: “The completion of the first procedures using the JAZZ system in China marks a major strategic milestone for IMPLANET. It is the result of several years of close collaboration with our partner Sanyou Medical, from regulatory registration to clinical deployment. The CFDA approval and the successful first surgeries are a testament to the clinical value of the JAZZ system in a key market, the largest in the world by volume potential. We are especially proud of the training and knowledge transfer achieved with the support of leading French spine surgeons, ensuring the system is used in line with the highest international standards of quality and safety. The upcoming surgeries scheduled in Shanghai and Beijing reflect our ambition to support a structured, progressive, and sustainable rollout of the JAZZ system across China’s major reference hospitals.”
Copy to clipboard 
